Neurocognitive Risk With PCSK9 Inhibitors: Need for More Robust Evidence. | J Am Coll Cardiol;69(19): 2468-2469, 2017 05 16. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Neurocognitive Risk With PCSK9 Inhibitors: Need for More Robust Evidence.

Khan, Abdur Rahman; Riaz, Haris; Farid, Talha; Bolli, Roberto.

J Am Coll Cardiol ; 69(19): 2468-2469, 2017 05 16.

Article in En | MEDLINE | ID: mdl-28494987

Subject(s)

Lipoproteins, LDL; Proprotein Convertase 9; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cholesterol; Randomized Controlled Trials as Topic

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proprotein Convertase 9 / Lipoproteins, LDL Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Language: En Journal: J Am Coll Cardiol Year: 2017 Document type: Article Country of publication: United States

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proprotein Convertase 9 / Lipoproteins, LDL Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Language: En Journal: J Am Coll Cardiol Year: 2017 Document type: Article Country of publication: United States